Covered recipient · General Payments record
JESSICA R ALLEGRETTI
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$201,022.99
113 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $117,740.62 | 32 |
| Consulting Fee | $67,784.63 | 21 |
| Travel and Lodging | $13,201.52 | 28 |
| Food and Beverage | $2,296.22 | 32 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $83,361.80 | 41 |
| Janssen Biotech, Inc. | $70,359.84 | 44 |
| PFIZER INC. | $22,348.31 | 8 |
| Ferring Pharmaceuticals Inc. | $7,328.31 | 7 |
| Janssen Global Services, LLC | $5,737.50 | 3 |
| Celltrion USA Inc. | $4,265.50 | 3 |
| Genentech, Inc. | $2,550.00 | 2 |
| Janssen Scientific Affairs, LLC | $2,337.50 | 1 |
| Janssen Research & Development, LLC | $1,895.00 | 2 |
| Eli Lilly and Company | $800.00 | 1 |
| Medtronic, Inc. | $39.23 | 1 |
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JESSICA R ALLEGRETTI
NPI 1992932453 · CMS profile ID 1103576
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992932453?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992932453?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992932453?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JESSICA R ALLEGRETTI, NPI 1992932453, CMS profile ID 1103576, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992932453?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
113 matching records · $201,022.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–113 of 113.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celltrion USA Inc. | $299.00 | 02/05/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250817833 | CMS |
| ABBVIE INC. | $850.00 | 02/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201398626 | CMS |
| Janssen Biotech, Inc. | $3,825.00 | 02/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174631172 | CMS |
| Janssen Biotech, Inc. | $98.49 | 01/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174638491 | CMS |
| Janssen Biotech, Inc. | $117.91 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174633894 | CMS |
| Janssen Biotech, Inc. | $188.75 | 01/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174637279 | CMS |
| Janssen Biotech, Inc. | $5,950.00 | 01/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174638107 | CMS |
| ABBVIE INC. | $2,100.00 | 01/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201398624 | CMS |
| Janssen Biotech, Inc. | $124.97 | 01/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174633365 | CMS |
| Janssen Biotech, Inc. | $957.28 | 01/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174633389 | CMS |
| Janssen Global Services, LLC | $1,062.50 | 01/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173804877 | CMS |
| Genentech, Inc. | $850.00 | 01/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211524024 | CMS |
| Janssen Scientific Affairs, LLC | $2,337.50 | 01/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174170159 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $8,648.70 | 15 |
| PY2025 | Principal investigator | $285,274.70 | 49 |
| PY2024 | Recipient | $14,903.08 | 15 |
| PY2024 | Principal investigator | $367,846.08 | 28 |
| PY2023 | Recipient | $3,330.00 | 5 |
| PY2023 | Principal investigator | $325,059.58 | 21 |
| PY2022 | Recipient | $9,250.00 | 8 |
| PY2022 | Principal investigator | $397,246.35 | 26 |
| PY2021 | Recipient | $14,750.00 | 11 |
| PY2021 | Principal investigator | $440,686.24 | 35 |
| PY2020 | Recipient | $10,510.00 | 6 |
| PY2020 | Principal investigator | $254,489.94 | 31 |
| PY2019 | Principal investigator | $545,453.77 | 34 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
64 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,337.00 | 12/19/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541920 |
| Principal investigator 1 | Eli Lilly and Company | $388.40 | 12/08/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187872797 |
| Recipient | F. Hoffmann-La Roche AG | $157.91 | 12/02/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536614 |
| Recipient | F. Hoffmann-La Roche AG | $234.69 | 12/02/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536627 |
| Principal investigator 1 | Genentech, Inc. | $1,658.00 | 11/25/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541998 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,694.00 | 11/21/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226147158 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $472.00 | 11/12/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226147151 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,659.00 | 11/12/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226147154 |
| Recipient | F. Hoffmann-La Roche AG | $163.94 | 11/10/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536607 |
| Recipient | F. Hoffmann-La Roche AG | $241.30 | 11/10/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536618 |
| Principal investigator 1 | Genentech, Inc. | $1,419.00 | 11/07/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211542002 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $26,478.31 | 10/10/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223264460 |
| Principal investigator 1 | ABBVIE INC. | $14,899.95 | 10/09/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202406943 |
| Recipient | F. Hoffmann-La Roche AG | $454.82 | 10/06/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536602 |
| Recipient | F. Hoffmann-La Roche AG | $896.83 | 10/05/2025 | Covered Recipient Physician | A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536621 |
| Principal investigator 1 | Genentech, Inc. | $1,342.00 | 10/03/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541990 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,337.00 | 09/23/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541916 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,304.00 | 09/04/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541912 |
| Principal investigator 1 | Genentech, Inc. | $1,219.14 | 09/03/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541966 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $850.00 | 08/27/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | No dispute reported | 06/30/2026 | 1242059743 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,640.00 | 08/26/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541907 |
| Principal investigator 1 | Genentech, Inc. | $1,219.14 | 08/21/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541973 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,766.00 | 08/07/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541891 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,000.00 | 07/31/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541887 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,852.00 | 07/31/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541895 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,089.00 | 07/31/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541899 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,500.00 | 07/31/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211541903 |
| Principal investigator 1 | Genentech, Inc. | $1,649.70 | 07/16/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 07/07/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | Prospective evaluation of ustekinumab dose intesification in inflammatory bowel diseases | No dispute reported | 06/30/2026 | 1175303636 |
| Principal investigator 1 | Genentech, Inc. | $2,074.00 | 06/19/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541940 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $2,700.00 | 06/13/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | No dispute reported | 06/30/2026 | 1242059730 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $250.00 | 06/13/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | No dispute reported | 06/30/2026 | 1242059734 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $4,225.00 | 06/13/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | No dispute reported | 06/30/2026 | 1242059740 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $17,787.00 | 06/05/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis | No dispute reported | 06/30/2026 | 1242059722 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $2,700.00 | 06/05/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis | No dispute reported | 06/30/2026 | 1242059724 |
| Principal investigator 1 | Genentech, Inc. | $4,087.98 | 05/21/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541959 |
| Principal investigator 1 | Genentech, Inc. | $2,379.00 | 05/15/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541947 |
| Principal investigator 1 | Genentech, Inc. | $2,174.00 | 05/08/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541950 |
| Recipient | F. Hoffmann-La Roche AG | $328.79 | 05/05/2025 | Covered Recipient Physician | RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis – Findings from the phase 2b TUSCANY-2 trial | No dispute reported | 06/30/2026 | 1211536623 |
| Recipient | F. Hoffmann-La Roche AG | $153.24 | 05/03/2025 | Covered Recipient Physician | Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis – Results from TUSCANY-2 | No dispute reported | 06/30/2026 | 1211536575 |
| Recipient | F. Hoffmann-La Roche AG | $181.85 | 05/03/2025 | Covered Recipient Physician | RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active Ulcerative Colitis – Findings from the phase 2b TUSCANY-2 trial | No dispute reported | 06/30/2026 | 1211536578 |
| Recipient | F. Hoffmann-La Roche AG | $387.08 | 05/03/2025 | Covered Recipient Physician | Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active Ulcerative Colitis – Results from TUSCANY-2 | No dispute reported | 06/30/2026 | 1211536610 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,146.89 | 04/25/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223264440 |
| Principal investigator 1 | Genentech, Inc. | $2,600.91 | 04/17/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541963 |
| Recipient | F. Hoffmann-La Roche AG | $103.57 | 04/14/2025 | Covered Recipient Physician | TUSCANY-2: A Dose-Ranging Phase 2b Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-like Ligand 1A (Anti-TL1A) in Adults with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536598 |
| Principal investigator 1 | Genentech, Inc. | $4,758.00 | 04/08/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541955 |
| Principal investigator 1 | Celgene Corporation | $2,000.00 | 04/01/2025 | Non-covered Recipient Entity Brigham And Womens Physicians Organization | Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222307207 |
| Recipient | F. Hoffmann-La Roche AG | $378.19 | 03/31/2025 | Covered Recipient Physician | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536582 |
| Recipient | F. Hoffmann-La Roche AG | $176.66 | 03/31/2025 | Covered Recipient Physician | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536585 |
| Recipient | F. Hoffmann-La Roche AG | $148.88 | 03/31/2025 | Covered Recipient Physician | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536590 |
| Recipient | F. Hoffmann-La Roche AG | $4,640.95 | 03/31/2025 | Covered Recipient Physician | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1211536594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,242.15 | 03/31/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | Prospective evaluation of ustekinumab dose intesification in inflammatory bowel diseases | No dispute reported | 06/30/2026 | 1175303707 |
| Principal investigator 1 | Amgen Inc. | $2,500.00 | 03/22/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1246637376 |
| Principal investigator 1 | Celgene Corporation | $2,000.00 | 03/04/2025 | Non-covered Recipient Entity Brigham And Womens Physicians Organization | A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222307159 |
| Principal investigator 1 | Celgene Corporation | $2,000.00 | 02/20/2025 | Non-covered Recipient Entity Brigham And Womens Physicians Organization | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 1222307221 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $2,700.00 | 02/13/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis | No dispute reported | 06/30/2026 | 1242059712 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $17,787.00 | 02/13/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis | No dispute reported | 06/30/2026 | 1242059717 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,500.00 | 02/12/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223264424 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 02/05/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541932 |
| Principal investigator 1 | Genentech, Inc. | $7,852.00 | 02/05/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541936 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 02/05/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211541943 |
| Principal investigator 1 | Genentech, Inc. | $2,365.74 | 01/14/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | RVT-3101-201 (TAHOE) | No dispute reported | 06/30/2026 | 1211541923 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,746.39 | 01/03/2025 | Covered Recipient Teaching Hospital Brigham And Womens Hospital | An Observational Study in Adults with Clostridioides difficile Infection to Determine the Feasibility and Logistics of Biospecimen Collection Transportation and Testing at Select US Study Sites | No dispute reported | 06/30/2026 | 1185543356 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $425.00 | 01/03/2025 | Covered Recipient Teaching Hospital BRIGHAM AND WOMENS HOSPITAL | REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | No dispute reported | 06/30/2026 | 1242059708 |